Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis
| Autor: | Rogério A. Costa, Ingrid U. Scott, Rodrigo Jorge, Daniela Calucci |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Vascular Endothelial Growth Factor A
Fovea Centralis medicine.medical_specialty genetic structures Bevacizumab Visual Acuity Angiogenesis Inhibitors Retinal Neovascularization Antibodies Monoclonal Humanized Injections Lesion Cellular and Molecular Neuroscience Retinal Diseases Optical coherence tomography Ophthalmology medicine Humans Telangiectasis Fluorescein Angiography Intravitreal bevacizumab Subretinal neovascularization medicine.diagnostic_test business.industry Fovea centralis Antibodies Monoclonal Retinal Vessels Middle Aged Fluorescein angiography eye diseases Sensory Systems Vitreous Body Treatment Outcome medicine.anatomical_structure Female sense organs Retinal Telangiectasis medicine.symptom business Tomography Optical Coherence medicine.drug |
| Zdroj: | Graefe's Archive for Clinical and Experimental Ophthalmology. 245:1045-1048 |
| ISSN: | 1435-702X 0721-832X |
| DOI: | 10.1007/s00417-006-0468-2 |
| Popis: | To describe the clinical, angiographic, and optical coherence tomography findings of a patient with subretinal neovascularization (SRN) in idiopathic juxtafoveolar retinal telangiectasis (IJRT) treated with intravitreal bevacizumab injection.In the setting of a tertiary referral center, a patient with bilateral acquired IJRT, complicated with juxtafoveal SRN in one eye, was treated with a single intravitreal injection of 1.5 mg of bevacizumab and then prospectively followed for 24 weeks.Vision improved from 20/40(-1) to 20/20(-2) by 24 weeks of follow-up. Fluorescein angiography demonstrated the absence of leakage from a previously active SRN. Optical coherence tomography revealed gradual neovascular lesion contraction and the resolution of subretinal fluid over the 24-week follow-up period. No obvious adverse events were noted.In the short-term, intravitreal bevacizumab treatment resulted in partial restoration of the macular architecture and vision improvement by means of neovascular lesion regression and the resolution of associated serohemorrhagic complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink